Literature DB >> 18843455

Changes of the soluble fibrin monomer complex level during the perioperative period of hip replacement surgery.

Tomonori Misaki1, Isao Kitajima, Tamon Kabata, Mineko Tani, Chiharu Kabata, Tsunehisa Tsubokawa, Hidesaku Asakura, Katsuro Tomita.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) is a critical complication after hip replacement surgery, so both early diagnosis and prophylaxis are important. The purpose of this study was to clarify the rapid changes of the fibrin monomer complex (FMC) and soluble fibrin (SF) during the perioperative period of hip replacement surgery.
METHODS: The subjects were 32 patients (7 men, 25 women) who underwent elective hip replacement surgery between November 2004 and January 2006. Their ages ranged between 34 to 82 years (mean 56.8 years). According to their thromboembolic risk, the patients received different prophylaxis: unfractionated heparin (4 patients), danaparoid sodium (14 patients), or mechanical therapy only (14 patients).
RESULTS: FMC and SF became rapidly elevated during the operation and just after surgery but declined to preoperational levels 3 days after surgery; they were higher in lupus anticoagulant (LA)-positive patients. In contrast, FDP and D-dimer had gradually become elevated 3 and 7 days after surgery. According to venous ultrasonography and lung perfusion scintigraphy, VTE occurred in 7 patients overall (21.9%). The incidence of VTE was 7.1% in the danaparoid group, whereas it was 35.7% in the mechanical therapy group. We also found that danaparoid sodium rapidly decreased FMC and SF within 3 days.
CONCLUSIONS: FMC and SF were rapidly elevated during hip replacement surgery and differentiated in LA-positive and LA-negative patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843455     DOI: 10.1007/s00776-008-1266-y

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  7 in total

1.  Less deep vein thrombosis due to transcutaneous fibular nerve stimulation in total knee arthroplasty: a randomized controlled trial.

Authors:  Masashi Izumi; Masahiko Ikeuchi; Koji Aso; Natsuki Sugimura; Yuko Kamimoto; Tetsuya Mitani; Tadashi Ueta; Takayuki Sato; Masataka Yokoyama; Tetsuro Sugiura; Toshikazu Tani
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-06-24       Impact factor: 4.342

2.  Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism.

Authors:  Christopher Kabrhel; D Mark Courtney; Carlos A Camargo; Michael C Plewa; Kristen E Nordenholz; Christopher L Moore; Peter B Richman; Howard A Smithline; Daren M Beam; Jeffrey A Kline
Journal:  Acad Emerg Med       Date:  2010-06       Impact factor: 3.451

Review 3.  What Is the Biological and Clinical Relevance of Fibrin?

Authors:  Rustem I Litvinov; John W Weisel
Journal:  Semin Thromb Hemost       Date:  2016-04-07       Impact factor: 4.180

4.  Changes in soluble fibrin levels during the perioperative period of gynecologic cancer surgery.

Authors:  Junichi Kodama; Noriko Seki; Chikako Fukushima; Tomoyuki Kusumoto; Keiichiro Nakamura; Atsushi Hongo; Yuji Hiramatsu
Journal:  Oncol Lett       Date:  2012-08-31       Impact factor: 2.967

Review 5.  [Diagnostic assessment of perioperative thromboembolism].

Authors:  Thomas Lang
Journal:  Wien Med Wochenschr       Date:  2009-10

6.  Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials.

Authors:  Yohko Kawai; Takeshi Fuji; Satoru Fujita; Tetsuya Kimura; Kei Ibusuki; Kenji Abe; Shintaro Tachibana
Journal:  Thromb J       Date:  2016-12-01

7.  Associations between venous thromboembolism onset, D-dimer, and soluble fibrin monomer complex after total knee arthroplasty.

Authors:  Genya Mitani; Tomonori Takagaki; Kosuke Hamahashi; Kenji Serigano; Yutaka Nakamura; Masato Sato; Joji Mochida
Journal:  J Orthop Surg Res       Date:  2015-11-10       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.